Brain atrophy in seizure-free temporal lobe epilepsy: Implications for predicting pharmacoresistance by Keller, Simon S
For Review Only
 
 
 
 
 
 
Brain atrophy in seizure-free temporal lobe epilepsy: 
implications for predicting pharmacoresistance 
 
 
Journal: Epilepsia 
Manuscript ID Draft 
Manuscript Type: Letter 
Date Submitted by the Author: n/a 
Complete List of Authors: Keller, Simon; University of Liverpool, Molecular and Clinical 
Pharmacology; King's College London, Department of Clinical Neuroscience 
Key Words: Prognosis, Imaging, Outcome, Atrophy 
  
 
 
Epilepsia
For Review Only
Brain atrophy in seizure-free temporal lobe epilepsy:  
implications for predicting pharmacoresistance 
 
 
 
Simon S. Keller 
 
Department of Molecular and Clinical Pharmacology, Institute of Translational 
Medicine, University of Liverpool 
Department of Neuroradiology, Walton Centre NHS Foundation Trust 
Department of Basic and Clinical Neuroscience, Institute of Psychiatry, 
Psychology & Neuroscience, King’s College London 
 
 
 
 
Dr. Simon S. Keller 
Department of Molecular and Clinical Pharmacology 
Institute of Translational Medicine 
University of Liverpool 
Clinical Sciences Centre 
Lower Lane 
Liverpool, L9 7LJ 
simon.keller@liverpool.ac.uk 
Tel: +44 (0)151 529 5461 
 
 
 
 
  
Page 1 of 4 Epilepsia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
To the Editors: 
I read with interest the recent manuscript by Alvim et al.1 entitled “Progression 
of gray matter atrophy in seizure-free patients with temporal lobe epilepsy”. 
Using voxel-based morphometry (VBM) applied to conventional 3D T1-
weighted images, the authors report widespread extrahippocampal atrophy in 
patients with well-controlled temporal lobe seizures, and that progressive 
atrophy occurs over time in the absence of recurrent seizures. As the authors 
point out, this suggests that “extrahippocampal atrophy has multifactorial 
causes and cannot be defined as the origin of the pharmacoresistance. 
Although seizures might be responsible to some extent for this atrophy, this 
probably does not influence the AED response” (pg 8). This work could be 
interpreted to indicate that more widespread brain atrophy is not necessarily a 
reflection of a seizure disorder that is less amenable to pharmacological or 
surgical therapy. This idea is not entirely consistent with the authors’ previous 
interesting papers, which indicate – using the same VBM techniques – that 
pharmacological2 and surgical3 control of temporal lobe seizures is less likely 
in patients with more widespread atrophy.  
 
TLE is a network disorder. Diffusion tensor imaging (DTI) studies are 
increasingly reporting that seizure freedom after temporal lobe surgery is less 
likely when deficits are observed in temporal lobe pathways.4, 5 Given the 
current paucity of data, it is currently unknown whether pharmacoresistance 
can be predicted using similar approaches in patients with a new diagnosis of 
TLE. Magnetic resonance spectroscopy may offer important insights.6 
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A crucial point is that the development of robust, individualized, imaging 
prognostic markers of treatment outcome in TLE is more likely to be achieved 
using imaging approaches that provide biological information that exceeds 
what is afforded by conventional structural MRI scans, which are typically 
acquired in context of the clinical evaluation of patients. The volumetric, 
thickness and surface area information afforded by conventional scans 
constrain inferences to macroscopic brain morphology. There is no doubt that 
these approaches have furthered our understanding of pathological brain 
changes in focal epilepsy. However, the ability to develop highly sensitive and 
robust prognostic imaging measures of treatment outcome – and a detailed 
understanding of the mechanisms underlying pharmacoresistance and 
postoperative outcome - are more likely to be achieved using imaging 
techniques that probe neurobiology on a microscopic scale. Diffusion 
approaches are not without limitation, but do represent an important 
development. Techniques that probe neuroinflammation may represent an 
important pathway,7 but there is of yet no evidence indicating that MRI can be 
used to directly, accurately and validly determi e neuroinflammation in 
epilepsy. In large scale imaging studies (i.e. >100 patients), imaging 
modalities are invariably restricted to what is collected for clinical purposes. 
New advanced imaging approaches that may have the sensitivity to 
discriminate between individual patients who will or will not achieve seizure 
remission are likely to be administered in context of research projects in 
smaller groups of patients, which limits the generalizability of findings. It may 
therefore be important to consider a coordinated effort across institutions to 
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harmonize advanced imaging protocols to identify non-invasive markers of 
seizure control.  
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